Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the effect of NASH (non-alcoholic steatohepatitis) on
the disposition of 99mTechnetium(Tc)-mebrofenin and to relate changes in 99mTc-mebrofenin
disposition to differences in the bile acid profile and Fibroscan Fibrosis Score of healthy
subjects compared to patients with NASH.
Phase:
Phase 1
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
National Institute of General Medical Sciences (NIGMS)